Abstract
Regadenoson (REG), a selective A2A receptor vasodilator, has not been widely evaluated in stress echocardiography (SE). We report results of 45 patients participating in REG + atropine (REGAT) SE protocol conducted in a single-center prospective trial. The REGAT study enrolled subjects before a clinically indicated cardiac catheterization for suspected coronary artery disease (CAD). After rest imaging, a 2 mg Atropine (AT) bolus followed by 400 mcg of REG was given. Standard stress imaging views were obtained and interpreted in blinded fashion. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) were calculated using cardiac catheterization >70 % stenosis as gold standard. Additional endpoints included major adverse cardiac events (MACE) and patient questionnaire responses. The mean duration of REGAT was 18 ± 7.2 min. There were no MACE, with only transient side-effects of dry mouth, shortness of breath, and headache. The incidence of significant CAD was 51.1 %. The sensitivity and specificity for significant stenosis was 60.9 and 86.4 %, with a PPV and NPV of 82.4 and 67.9 %. By coronary territories, the sensitivity, specificity, PPV, and NPV were: left anterior descending artery 58.8, 92.9, 83.3, and 78.8 %; left circumflex artery 6.7, 93.3, 33.3, and 67.7 %; and right coronary artery 16.7, 93.9, 50, and 75.6 %. Over 90 % of subjects reported feeling comfortable, with 83 % preferring REGAT as a future stress modality. The REGAT protocol is fast, safe, and well-tolerated with good specificity for CAD detection, but its low sensitivity and NPV precludes it from being an imaging modality for routine use.
Similar content being viewed by others
References
Salustri A, Fioretti PM, McNeill AJ, Pozzoli MM, Roelandt JR (1992) Pharmacological stress echocardiography in the diagnosis of coronary artery disease and myocardial ischaemia: a comparison between dobutamine and dipyridamole. Eur Heart J 13:1356–1362
Picano E, Bedetti G, Varga A, Cseh E (2000) The comparable diagnostic accuracies of dobutamine-stress and dipyridamole-stress echocardiographies: a meta-analysis. Coron Artery Dis 11:151–159
Astarita C, Palinkas A, Nicolai E, Maresca FS, Varga A, Picano E (2001) Dipyridamole-atropine stress echocardiography versus exercise SPECT scintigraphy for detection of coronary artery disease in hypertensives with positive exercise test. J Hypertens 19:495–502
Scherhag AW, Pfleger S, Schreckenberger AB, Gruttner J, Voelker W, Staedt U, Heene DL (1997) Detection of patients with restenosis after PTCA by dipyridamole-atropine-stress-echocardiography. Int J Card Imaging 13:115–123
Lanzarini L, Fetiveau R, Poli A, Diotallevi P, Barberis P, Previtali M (1995) Results of dipyridamole plus atropine echo stress test for the diagnosis of coronary artery disease. Int J Card Imaging 11:233–240
Fukai T, Koyanagi S, Tashiro H, Ichiki T, Tsutsui H, Matsumoto T, Takeshita A (1995) Adenosine triphosphate stress echocardiography in the detection of myocardial ischemia. Am J Card Imaging 9:237–244
Tawa CB, Baker WB, Kleiman NS, Trakhtenbroit A, Desir R, Zoghbi WA (1996) Comparison of adenosine echocardiography, with and without isometric handgrip, to exercise echocardiography in the detection of ischemia in patients with coronary artery disease. J Am Soc Echocardiogr 9:33–43
Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, Lieu H, Mahmarian JJ, Olmsted A, Underwood SR, Vitola J, Wang W (2007) Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 14:645–658
Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, Moye LA, Olmsted AW (2009) Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2:959–968
Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE (2008) Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 1:307–316
Takeishi Y, Chiba J, Abe S, Ikeda K, Tomoike H (1994) Adenosine-echocardiography for the detection of coronary artery disease. J Cardiol 24:1–7
Harada M, Okura K, Nishizawa S, Inoue T, Sakai H, Lee T, Sugiyama Y, Suzuki M, Hirai H, Yamaguchi T (1998) Detection of coronary artery disease by adenosine triphosphate stress echocardiography: comparison with adenosine triphosphate stress thallium myocardial scintigraphy and coronary angiography. J Cardiol 32:163–171 (in Japanese)
Picano E, Pingitore A, Conti U, Kozakova M, Boem A, Cabani E, Ciuti M, Distante A, L’Abbate A (1993) Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dipyridamole echocardiography. Eur Heart J 14:1216–1222
Henzlova MJ, Cerqueira MD, Mahmarian JJ, Yao SS (2006) Stress protocols and tracers. J Nucl Cardiol 13:e80–e90
Ranhosky A, Kempthorne-Rawson J (1990) The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group. Circulation 81:1205–1209
Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, Burns PN, Castello R, Coon PD, Hagen ME, Jollis JG, Kimball TR, Kitzman DW, Kronzon I, Labovitz AJ, Lang RM, Mathew J, Moir WS, Nagueh SF, Pearlman AS, Perez JE, Porter TR, Rosenbloom J, Strachan GM, Thanigaraj S, Wei K, Woo A, Yu EH, Zoghbi WA (2008) American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr 21:1179–1201
Pellikka PA, Nagueh SF, Elhendy AA, Kuehl CA, Sawada SG (2007) American Society of Echocardiography recommendations for performance, interpretation, and application of stress echocardiography. J Am Soc Echocardiogr 20:1021–1041
Bartunek J, Marwick TH, Rodrigues AC, Vincent M, Van Schuerbeeck E, Sys SU, de Bruyne B (1996) Dobutamine-induced wall motion abnormalities: correlations with myocardial fractional flow reserve and quantitative coronary angiography. J Am Coll Cardiol 27:1429–1436
Iskandrian AS, Verani MS, Heo J (1994) Pharmacologic stress testing: mechanism of action, hemodynamic responses, and results in detection of coronary artery disease. J Nucl Cardiol 1:94–111
Chan SY, Brunken RC, Czernin J, Porenta G, Kuhle W, Krivokapich J, Phelps ME, Schelbert HR (1992) Comparison of maximal myocardial blood flow during adenosine infusion with that of intravenous dipyridamole in normal men. J Am Coll Cardiol 20:979–985
Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD (1990) Effects of adenosine on human coronary arterial circulation. Circulation 82:1595–1606
Voudris V, Manginas A, Vassilikos V, Koutelou M, Kantzis J, Cokkinos DV (1996) Coronary flow velocity changes after intravenous dipyridamole infusion: measurements using intravascular Doppler guide wire. A documentation of flow inhomogeneity. J Am Coll Cardiol 27:1148–1155
Picano E, Marini C, Pirelli S, Maffei S, Bolognese L, Chiriatti G, Chiarella F, Orlandini A, Seveso G, Colosso MQ et al (1992) Safety of intravenous high-dose dipyridamole echocardiography. The Echo-Persantine International Cooperative Study Group. Am J Cardiol 70:252–258
Sicari R, Pasanisi E, Venneri L, Landi P, Cortigiani L, Picano E (2003) Stress echo results predict mortality: a large-scale multicenter prospective international study. J Am Coll Cardiol 41:589–595
Coletta C, Galati A, Greco G, Burattini M, Ricci R, Carunchio A, Fera MS, Bordi L, Ceci V (1995) Prognostic value of high dose dipyridamole echocardiography in patients with chronic coronary artery disease and preserved left ventricular function. J Am Coll Cardiol 26:887–894
Pingitore A, Picano E, Colosso MQ, Reisenhofer B, Gigli G, Lucarini AR, Petix N, Previtali M, Bigi R, Chiaranda G, Minardi G, de Alcantara M, Lowenstein J, Sclavo MG, Palmieri C, Galati A, Seveso G, Heyman J, Mathias W Jr, Casazza F, Sicari R, Raciti M, Landi P, Marzilli M (1996) The atropine factor in pharmacologic stress echocardiography. Echo Persantine (EPIC) and Echo Dobutamine International Cooperative (EDIC) Study Groups. J Am Coll Cardiol 27:1164–1170
Cortigiani L, Picano E, Landi P, Previtali M, Pirelli S, Bellotti P, Bigi R, Magaia O, Galati A, Nannini E (1998) Value of pharmacologic stress echocardiography in risk stratification of patients with single-vessel disease: a report from the Echo-Persantine and Echo-Dobutamine International Cooperative Studies. J Am Coll Cardiol 32:69–74
Pingitore A, Picano E, Varga A, Gigli G, Cortigiani L, Previtali M, Minardi G, Colosso MQ, Lowenstein J, Mathias W Jr, Landi P (1999) Prognostic value of pharmacological stress echocardiography in patients with known or suspected coronary artery disease: a prospective, large-scale, multicenter, head-to-head comparison between dipyridamole and dobutamine test. Echo-Persantine International Cooperative (EPIC) and Echo-Dobutamine International Cooperative (EDIC) Study Groups. J Am Coll Cardiol 34:1769–1777
Cortigiani L, Lombardi M, Michelassi C, Paolini EA, Nannini E (1998) Significance of myocardial ischemic electrocardiographic changes during dipyridamole stress echocardiography. Am J Cardiol 82:1008–1012
Marwick T, Willemart B, D’Hondt AM, Baudhuin T, Wijns W, Detry JM, Melin J (1993) Selection of the optimal nonexercise stress for the evaluation of ischemic regional myocardial dysfunction and malperfusion. Comparison of dobutamine and adenosine using echocardiography and 99mTc-MIBI single photon emission computed tomography. Circulation 87:345–354
Kim C, Kwok YS, Heagerty P, Redberg R (2001) Pharmacologic stress testing for coronary disease diagnosis: a meta-analysis. Am Heart J 142:934–944
Gordi T, Blackburn B, Lieu H (2007) Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 47:825–833
Porter TR, Adolphson M, High RR, Smith LM, Olson J, Erdkamp M, Xie F, O’Leary E, Wong BF, Eifert-Rain S, Hagen ME, Abdelmoneim SS, Mulvagh SL (2011) Rapid detection of coronary artery stenoses with real-time perfusion echocardiography during regadenoson stress. Circ Cardiovasc Imaging 4:628–635
Acknowledgments
This study was investigator initiated and funded by Astellas Pharma US, Inc. We thank Stephanie Stebens MLIS from Sladen Library Henry Ford Hospital for her expert assistance formatting the manuscript.
Conflict of interest
Dr Ananthasubramaniam receives research grants from Astellas Pharma US Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shaikh, K., Wang, D.D., Saad, H. et al. Feasibility, safety and accuracy of regadenoson–atropine (REGAT) stress echocardiography for the diagnosis of coronary artery disease: an angiographic correlative study. Int J Cardiovasc Imaging 30, 515–522 (2014). https://doi.org/10.1007/s10554-014-0363-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10554-014-0363-6